BioNTech and BMS Drug Combination Shows Promise in Advanced Lung Cancer

Initial Phase 2 trial data for pumitamig combined with docetaxel, from BioNTech and Bristol Myers Squibb, indicates encouraging anti-tumor activity in metastatic non-small cell lung cancer patients who progressed after prior immunotherapy. The trial reported a 36.7% objective response rate and 90.0% disease control rate, with a median progression-free survival of 6.9 months. This suggests a potential new treatment option for a challenging patient population.